Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Poll|May 3, 2018
Mini Quiz: Treatment-Resistant Bipolar Disorder
Author(s)Charles B. Schaffer, MD
What are the guidelines for working with patients who do not respond to FDA-approved medications for bipolar disorder?
Advertisement
Which of the following interventions can be useful in treating treatment-resistant bipolar disorder?
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5